MX369414B - Peptido. - Google Patents

Peptido.

Info

Publication number
MX369414B
MX369414B MX2015009085A MX2015009085A MX369414B MX 369414 B MX369414 B MX 369414B MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 369414 B MX369414 B MX 369414B
Authority
MX
Mexico
Prior art keywords
peptide
apitope
mog
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Application number
MX2015009085A
Other languages
English (en)
Other versions
MX2015009085A (es
Inventor
David Wraith
Original Assignee
Apitope Tech Bristol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Tech Bristol Limited filed Critical Apitope Tech Bristol Limited
Publication of MX2015009085A publication Critical patent/MX2015009085A/es
Publication of MX369414B publication Critical patent/MX369414B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Abstract

La presente invención se refiere a un péptido que es capaz de unirse a una molécula del MHC in vitro y de ser presentado a una célula T sin procesamiento del antígeno, en donde dicho péptido se selecciona de los siguientes péptidos de la glucoproteína de oligodendrocitos de la mielina (MOG), MOG 41-55 (SEQ ID NO: 1), 43-57 (SEQ ID NO: 2) , 44-58 (SEQ ID NO:3) y 45-59 (SEQ ID NO: 4), para usarse en el tratamiento y/o prevención de una enfermedad desmielinizante al unirse al MHC clase II en células que presenta antígeno (APCs) e inducir anergia y tolerancia de células T.
MX2015009085A 2013-01-15 2014-01-13 Peptido. MX369414B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (2)

Publication Number Publication Date
MX2015009085A MX2015009085A (es) 2016-02-16
MX369414B true MX369414B (es) 2019-11-07

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009085A MX369414B (es) 2013-01-15 2014-01-13 Peptido.

Country Status (16)

Country Link
US (2) US9862751B2 (es)
EP (1) EP2945966B1 (es)
JP (1) JP6347065B2 (es)
KR (1) KR102169902B1 (es)
CN (1) CN105121463B (es)
AU (1) AU2014206592B2 (es)
BR (1) BR112015016780A2 (es)
CA (1) CA2897655C (es)
GB (1) GB201300684D0 (es)
HK (1) HK1211596A1 (es)
IL (1) IL239871B (es)
MX (1) MX369414B (es)
RU (1) RU2675479C2 (es)
SG (1) SG11201505526TA (es)
WO (1) WO2014111840A2 (es)
ZA (1) ZA201504987B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (zh) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 一种诱导食蟹猴实验性自身免疫性脑脊髓炎动物模型的蛋白和应用
CN111225681A (zh) * 2017-08-14 2020-06-02 艾匹托普技术(布里斯托尔)有限公司 方法
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170901A1 (en) 1993-09-03 1995-03-09 Brigitte Devaux Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
CA2250361A1 (en) 1996-03-28 1997-10-02 Barbara Wallner Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (sv) 1997-09-11 1997-09-11 Astra Ab Peptides
EP1168923B1 (en) 1999-03-12 2005-11-02 The Board Of Trustees Of The Leland Stanford Junior University Dna vaccination for treatment of autoimmune disease
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
WO2001072325A1 (en) 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
WO2002016410A2 (en) 2000-08-21 2002-02-28 Apitope Technology (Bristol) Limited Peptide selection method
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL161121A0 (en) 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
PT2363710E (pt) 2002-08-08 2015-10-01 Baylor College Medicine Isolamento e identificação de células t
US20070042945A1 (en) 2002-09-25 2007-02-22 Genentech, Inc. Nouvelles compositions et methods de traitement du psoriasis
JP2008500006A (ja) 2003-05-21 2008-01-10 バイオテック トゥールス ソシエテ アノニム ペプチド複合体
ES2559409T3 (es) 2003-09-05 2016-02-12 Oregon Health & Science University Moléculas de MHC recombinantes monoméricas útiles para la manipulación de células T específicas de antígenos
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
EP1827108B1 (en) 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
EP1858548B1 (en) 2005-03-14 2012-06-20 Yeda Research And Development Co., Ltd. Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
JP5312028B2 (ja) 2005-09-28 2013-10-09 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
WO2007061805A2 (en) 2005-11-17 2007-05-31 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1991259B1 (en) 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US20080317710A1 (en) 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
NZ572644A (en) 2006-05-05 2012-06-29 Opexa Therapeutics T-cell vaccine
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
CN104650225B (zh) 2006-10-27 2019-10-01 勒帕斯公司 用于结合鞘氨醇-1-磷酸的组合物和方法
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MY158800A (en) * 2007-10-31 2016-11-15 Apitope Tech (Bristol) Ltd Composition
EP2245059B1 (en) 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
WO2010045265A1 (en) 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
BRPI0920430A2 (pt) 2008-10-22 2019-09-24 Revalesio Corp composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP2012508865A (ja) 2008-11-12 2012-04-12 イエダ リサーチ アンド ディベロプメント カンパニー リミテッド 多発性硬化症の診断
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010126908A1 (en) 2009-04-27 2010-11-04 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
CN106237331A (zh) 2009-12-09 2016-12-21 田边三菱制药株式会社 T细胞活化抑制剂、含有其的药物组合物以及抑制t细胞活化的物质的筛选方法
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
PL217128B1 (pl) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
US8901074B2 (en) 2010-08-04 2014-12-02 Ramot At Tel-Aviv University Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases
WO2012019041A2 (en) 2010-08-04 2012-02-09 Duke University Regulatory b cells and their uses
EA201300228A1 (ru) 2010-08-12 2013-06-28 Ревалезио Корпорейшн Композиции и способы лечения таупатии
WO2012031258A1 (en) 2010-09-03 2012-03-08 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
US20120076808A1 (en) 2010-09-27 2012-03-29 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
WO2012117075A2 (en) 2011-03-01 2012-09-07 Pharnext Treatment of cerebral ischemia
JP5878447B2 (ja) 2012-09-12 2016-03-08 富士フイルム株式会社 ベースメイク化粧料
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
AU2014206592B2 (en) 2018-01-04
US20180086802A1 (en) 2018-03-29
BR112015016780A2 (pt) 2017-08-15
JP6347065B2 (ja) 2018-06-27
ZA201504987B (en) 2017-11-29
WO2014111840A2 (en) 2014-07-24
CA2897655A1 (en) 2014-07-24
US9862751B2 (en) 2018-01-09
IL239871B (en) 2018-12-31
IL239871A0 (en) 2015-08-31
EP2945966B1 (en) 2019-07-03
US20150353616A1 (en) 2015-12-10
AU2014206592A1 (en) 2015-07-23
CN105121463B (zh) 2020-11-27
KR20150105365A (ko) 2015-09-16
RU2675479C2 (ru) 2018-12-19
EP2945966A2 (en) 2015-11-25
CA2897655C (en) 2023-04-04
RU2015134356A (ru) 2017-02-22
WO2014111840A3 (en) 2014-10-30
KR102169902B1 (ko) 2020-10-26
SG11201505526TA (en) 2015-08-28
US10377800B2 (en) 2019-08-13
JP2016505008A (ja) 2016-02-18
HK1211596A1 (en) 2016-05-27
GB201300684D0 (en) 2013-02-27
CN105121463A (zh) 2015-12-02
MX2015009085A (es) 2016-02-16

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
AU2017296095B2 (en) Multispecific antibodies against CD40 and CD137
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201590388A1 (ru) Способы лечения таупатии
MX342675B (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
MX2016016419A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2015009085A (es) Peptido.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3

Legal Events

Date Code Title Description
FG Grant or registration